Clemex finalizes the strategic alliance with RAL Diagnostics

MONTREAL, Sept. 8, 2011 /CNW/ -- 
The alliance based on a Share Swap between the two Corporations licenses
European market distribution of the new Clemex system for Haematology
 applications


Symbol:  CXG.A-TSX-V 
www.clemex.com
Shares Outstanding:  23,999,810


MONTREAL, Sept. 8, 2011 /CNW Telbec/ - Clemex Technologies Inc. (TSXV:
 CXG.A) announces it has received the TSX Exchange approval and has
 finalized the strategic alliance with its European partner RAL
 Diagnostics located in Martillac, France, to whom no previous business
 links existed. This alliance will notably support the marketing of its
 new instrument being developed for the Haematology sector. According to
 the partnership signed between the two Corporations, RAL will
 immediately become the exclusive distributor of the new microscopy
 instruments developed by Clemex for haematology and other life sciences
 applications in Europe.


Clemex, on the other hand, developed its new instrument for haematology
 to primarily use the new MCDH stain solution created by RAL and will
 also engage in working to develop new microscopy instruments in the
 future using the various staining solutions created and manufactured by
 RAL.


A commercial partnership in Europe


RAL Diagnostic immediately becomes dealer of other image analysis
 products manufactured by Clemex for all other microscopy applications
 in France, Belgium and Switzerland. Finally, RAL will become the
 privileged business partner of Clemex products for all of Europe within
 a year, and will eventually become in charge of all commercial
 activities such as distribution and marketing for all of Europe. With
 such an important partner, Clemex, which was only partially present in
 Europe, will strengthen its presence and should increase its sales
 significantly to reach North America sales levels in the near future.


Business transaction


With completion of this transaction, Clemex holds 10% of RAL Diagnostics
 share capital. RAL obtains in return 3 250 000 voting shares issued by
 Clemex, representing 13.5% of all outstanding voting shares issued by
 the Company. RAL Diagnostics, which already held 750 000 shares from a
 private placement concluded in 2008, will then hold, 16.7% of the
 outstanding voting shares of Clemex.


Financial Information


RAL, which has a complementary microscopy line of products to those of
 the image analysis microscopy products sold by Clemex, has a Sales
 Volume, Net Equity and a Company size of about 30% higher than Clemex.


(In Canadian dollars) 


 _____________________________________________________________________
|       | Total | Total |  Net  |  Sales  |Sales in|  Net   |  Nbr.   |
|       |Assets | Debts |Equity,|volume of|  2011  | Income |   Of    |
|       | March | March | March |the last |  (12   |in 2011,|Employees|
|       |  31,  |  31   |  31   |4 fiscal |months) |  (12   |         |
|       | 2011  | RAL   | 2011, |years (12|        |months) |         |
|       | RAL   |(April |  RAL  | months  |        |        |         |
|       |(April |  30   |  (30  |periods) |        |        |         |
|       | 30    | 2011, |avril, |         |        |        |         |
|       | 2011, |Clemex)| 2011, |         |        |        |         |
|       |Clemex)|       |Clemex)|         |        |        |         |
|_______|_______|_______|_______|_________|________|________|_________|
|       |    $  |    $  |    $  |      $  |     $  |     $  |         |
|_______|_______|_______|_______|_________|________|________|_________|
|       |  4,7 M|  2,5 M|  2.2 M|         |        |        |         |
|RAL(1 )|  (2)  |  (3)  |  (4)  |  25.8 M |  6.6 M |510 276 |     40  |
|_______|_______|_______|_______|_________|________|________|_________|
|Clemex | 2,9 M | 1,6 M | 1,3 M |  19.7 M |  5.3 M |323 070 |     28  |
|_______|_______|_______|_______|_________|________|________|_________|




Note 1; French accounting reports (unaudited), French standards,
 Accounting rules committee (ARC)
Note 2; 3,5 M Euros converted in Canadians dollars at a rate of 1.36
Note 3; 1.9 M Euros converted in Canadians dollars at a rate of 1.36
Note 4; 1,6 M Euros converted in Canadians dollars at a rate of 1.36 


About RAL Diagnostics


RAL Diagnostics is a manufacturer of biological stains intended for the
 field of human and animal health, scientific research, medical
 diagnosis, and industry. These stains are available in liquids or ready
 to use kits. RAL Diagnostics serves 6,000 medical analysis laboratories
 and anatomopathology laboratories of France thanks to a network of 35
 distributors and 180 representatives. The company is present in more
 than 40 countries in the world.


About Clemex Technologies Inc.


Clemex Technologies Inc. develops, manufactures and markets image
 analysis systems and software used by quality control and research
 microscopy laboratories.  Clemex customer base spans over many
 countries in America, Europe, Asia and encompasses major Research and
 Development Centers, prestigious Universities and large manufacturing
 industries in various fields including healthcare, automotive,
 aerospace, raw materials manufacturing, pharmaceuticals, mining and
 other sectors.


 


To view this news release in HTML formatting, please use the following URL: http://www.cnw.ca/en/releases/archive/September2011/08/c9642.html



p bClemex Technologies Inc,/bbr/ 800 Guimond,br/ Longueuil, QC, Canada J4G 1T5, /p p Contact: /p p align="justify" Clément Forgetbr/ Tel: [phone]br/ Email: a href="mailto:[e-mail]"[e-mail]/a /p 

Copyright